注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
De-Chao Yu | 58 | 2011 | Co-Founder, Chairman & CEO |
Kai-Xian Chen | 75 | 2018 | Independent Non-Executive Director |
Erwin Vanhaecke | - | - | Member of CMC Strategic Advisory Board |
Charles Leland Cooney | 78 | 2015 | Member of CMC Strategic Advisory Board & Independent Non-Executive Director |
David LaPre | - | - | Member of CMC Strategic Advisory Board |
Chiang Syin | 66 | - | Member of CMC Strategic Advisory Board |
Carlos Garcia-Echeverria | 57 | 2021 | Member of Scientific Advisory Board |
Lewis L. Lanier | - | 2021 | Member of Scientific Advisory Board |
Lawrence Fong | - | 2021 | Member of Scientific Advisory Board |
Gary J. Zieziula | 67 | 2022 | Independent Non-executive Director |
I-Yin Hsu | 48 | 2018 | Independent Non-Executive Director |
Hao Xi Ede | 65 | 2024 | Executive Director & Fund Managing Partner |
Shun Lu | - | 2024 | Independent Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核